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Chapter 4
Advanced Glycation End-Products are
Associated with the Presence and Severity
of Paratonia in Early Stage Alzheimer Disease
Hans Drenth, Sytse U. Zuidema, 
Wim P. Krijnen, Ivan Bautmans, 






Objective: Paratonia, a distinctive form of hypertonia in dementia patients, causes loss of 
functional mobility in early stage dementia to severe contractures and pain in the late stages. The 
pathogenesis of paratonia is not well understood. Patients in early stage dementia with Diabetes 
Mellitus (DM) showed a significantly higher risk for the development of paratonia. Both Alzheimer 
disease (AD) and DM are related to higher concentrations of advanced glycation end-products 
(AGEs). The purpose of this study is to explore the association of AGEs with the prevalence and 
severity of paratonia in patients with Alzheimer disease. 
Design: Observational longitudinal, 1-year follow-up cohort study with 3 assessments. 
Setting: Day care centers for patients with dementia. 
Participants: A total of 144 community-dwelling patients with early stage Alzheimer or Alzheimer/
vascular disease patients were recruited from 24 dementia day care centers in The Netherlands. 
Measurements: The presence of paratonia (Paratonia Assessment Instrument), the severity of 
paratonia (Modified Ashworth Scale for paratonia), and AGE levels (AGE-reader). 
Results:  From the 144 participants (56.3% female and 43.7% male, with a mean [standard 
deviation] age of 80.7 [7.7] years), 118 participants were available for final follow-up. A significant 
association between AGE levels and the presence of paratonia (odds ratio 3.47, 95% confidence 
interval [CI]: 1.87 – 6.44, P <.001) and paratonia severity (β = 0.17, 95% CI: 0.11 - 0.23, P <.001) 
was determined. In participants who developed paratonia and those with persistent paratonia 
throughout the study the AGE levels (95% CI: - 0.38 to - 0.13, P <.001 and 95% CI: -0.46 to - 0.06, 
P =.012, respectively) and the severity of paratonia (95% CI: -0.60 to - 0.35, P <.001 and 95%  
CI: -0.38 to - 0.12, P <.001, respectively) significantly increased, whereas the AGE levels remained 
stable in those participants without paratonia. Notwithstanding, change in AGE levels was not 
significantly (P =.062) related to change in paratonia severity, mixed model analyses provided 
evidence for both a significant time and between participant effect of AGEs on paratonia severity. 
Conclusions: This study suggests that elevated AGE levels are a contributing factor to paratonia 
and its severity and could be the result of peripheral biomechanical changes reducing elasticity 
and increasing stiffness. These results provide a new perspective on paratonia and gives rise to 
further research whether paratonia could be postponed or movement stiffness can be improved 
by reducing AGE levels.




A wide variety of movement disorders are reported in patients with dementia. Paratonia, a 
distinctive form of hypertonia, is one of these movement disorders and is characterized by 
an active unintentional resistance against passive movement 1. Paratonia has a prevalence 
of 10% in the early/mild stages, and up to 90-100% in later/severe stages of dementia. As 
dementia progresses, the severity of paratonia increases from actively assisting the passive 
movement (because of an inability to relax) and mild resistance towards severe high 
resistance and muscle tone which causes loss of mobility, severe contractures, and pain in 
the last stage of dementia 2,3. Resistance in paratonia is variable, in particular in the very early 
stages of dementia paratonia can fluctuate between no resistance,  actively assisting, and 
active resistance against passive movement 2–4. In early stage dementia, paratonia hampers 
functional mobility such as raising from a chair, walking and turning 2. The pathogenesis of 
paratonia is not well understood, and no effective interventions are available to prevent, 
postpone or combat paratonia. 
It has been shown that patients in early stage dementia with Diabetes Mellitus (DM) have 
a significantly higher risk for the development of paratonia in comparison with those with 
dementia but without DM 1.  Previous research also reported that DM is a risk factor for 
muscle rigidity in patients without dementia 5. Interestingly, both Alzheimer disease (AD) 
and DM are related to higher concentrations of advanced glycation end-products (AGEs), 
suggesting that AGEs could possibly be involved in the development of paratonia. The 
occurrence of AGEs is mediated by non-enzymatic condensation of a reducing sugar with 
an amino group 6–8. With aging, there is an imbalance between the formation and natural 
clearance of AGEs, which results in to an incremental accumulation in tissues 6–9. 
As stated before, the pathogenesis of paratonia is not well understood. Obviously with 
dementia, central nervous system pathology plays a role; yet, peripheral biomechanical 
changes are also suggested. In this perspective, it is of interest to know that the cross-linking 
processes by AGEs are responsible for an increasing proportion of insoluble extracellular 
matrix and thickening of the tissues, thereby increasing mechanical stiffness and loss of 
elasticity 6,10,11. Non-cross-linking effects occur through the binding of AGEs to the receptor 
for AGEs (RAGE). RAGE is a multi-ligand member of the immunoglobulin superfamily of cell 
surface molecules that is widely localized in a variety of cell lines, including endothelial, 
neuronal, smooth muscle, mesangial and monocytes 12.  AGE/RAGE binding subsequently 
incites activation of intracellular signalling, gene expression, and production of pro-
inflammatory cytokines and free radicals. At the peripheral (tissue) level, these inflammatory 
processes exhibit strong proteolytic activity by which the collagen becomes more vulnerable 
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and tissue elasticity decreases 12,13. At the central level (central nervous system), AGE/RAGE 
interaction appears to affect neuronal function 7,13.
The role of AGEs in the development of paratonia is currently unknown. The purpose of this 
study is to explore the association of AGEs with the prevalence and severity of paratonia in 
patients with AD. 
METHODS
Study Design and Ethical Consideration
This study was a multicenter, longitudinal, 1-year follow-up cohort study with 3 assessments; 
at baseline, after 6 months and after 12 months. The medical ethical committee of the 
University Medical Centre Groningen approved the study (NL43641.042.13).
Study Population
Participants, recruited from 24 dementia day care centers in The Netherlands, were 
considered to be eligible for inclusion in the study when they satisfied the following criteria: 
(1) an established diagnosis of AD or Alzheimer/vascular dementia (AD/VaD) according 
to DSM-IV criteria 14; (2) Early stage dementia; a score of stage 5 or lower on the global 
deterioration scale 15 and (3) having a light colored (Caucasian) skin (skin pigmentation 
influence AGE measurements 16). Written informed consent was obtained from patients or 
their legal representatives. Participants were excluded if they had an established diagnosis 
of dementia other than type AD or AD/VaD or were using first generation psychotropic 
drugs as these drugs can possibly mimic paratonic rigidity.
Outcome Measures
Paratonia
The presence of paratonia was assessed by trained and experienced physiotherapists by 
employing the Paratonia Assessment Instrument (PAI), a reliable and valid measurement 
based on a successively passive mobilization of both shoulders towards ante-flexion/retro-
flexion, elbows towards flexion/extension, and combined hips/knees towards extension/
flexion 17. With the participant in a sitting position the examiner began with a slow movement 
of the limb, after which the movement was accelerated. Paratonia was diagnosed as being 
present when the following five criteria are all met: (1) an involuntary variable resistance; 
(2) a degree of resistance that varied depending on the speed of the movement (e.g., a low 
resistance to slow movements and a high resistance to fast movement); (3) resistance to 
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passive movement in any direction; (4) no clasp-knife phenomenon; and (5) resistance in 
two movement directions in the same limb or two different limbs.
We used a Modified Ashworth Scale, validated to assess paratonia severity (MAS-P) as 
described by Waardenburg et al. 18. In the MAS-P  each category contains a tone and passive 
movement feature, thereby creating a more consistent scale for paratonia 18. During the 
PAI assessment, the assessor quantified the muscle tone based on the resistance induced 
by the passive movements of the limbs into a total of 12 MAS-P scores (the corresponding 
movement directions from the PAI). The MAS-P is based on a 5-point scale ranging from 0 
to 4, meaning 0 = no increase in muscle tone or no resistance during passive movement, 
1 = slight increase in muscle tone or slight resistance during passive movement, 2 = more 
marked increase in muscle tone or more marked resistance during passive movement, 
3 = considerable increase in muscle tone or considerable resistance during passive 
movement, and 4 = severe resistance such that passive movement is impossible. A score of 
0.5 was assigned in the event of active assistance. For further analyses the 12 scores were 
summarized as the average MAS-P value. The MAS-P shows acceptable reliability 18.
AGE levels
AGE levels were assessed by the main researcher through skin autofluorescence (SAF) by 
using an AGE Reader device (Diagnoptics, Groningen, The Netherlands). The AGE reader 
measures fluorescent skin tissue AGEs which correlate with non-fluorescent AGEs 19,20. The 
AGE reader is a desktop device that has a light source which illuminates the skin of the forearm 
and uses the fluorescent properties of AGEs to measure tissue accumulation of AGEs 19. SAF 
is calculated (by the AGE reader software) as the ratio between the emission light and the 
excitation light, multiplied by 100 and expressed in arbitrary units. An elevated SAF (arbitrary 
units) score  corresponds to a high tissue AGEs level 19. All AGE reader measurements 
were performed at room temperature in a standardized semi dark environment with the 
participants in a seated position and the volar side of the right forearm placed on top of the 
AGE reader. The measurements were performed on the skin without sweat, skin lotions, or 
visible skin abnormalities and with the assessor being blinded for PAI/MAS-P scores. The 
mean of 3 consecutive measurements was used. The AGE reader is reported to be a reliable 
and valid instrument for the quantification of AGEs accumulation 19,20.
Cognitive function and comorbidities
The diagnosis of dementia was established by the local physician or general practitioner 
based on the DSM-IV criteria. Dementia severity was staged by key staff personal using the 
global deterioration scale, which identifies 7 stages from no dementia to severe dementia 15. 
Cognitive function was measured by experienced psychologists or physicians with the 
Mini-Mental State Examination (MMSE) 21. The MMSE is an 11-item questionnaire with a 
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maximum score of 30 which (30 = no cognitive decline; 0 = very severe cognitive decline).
The comorbidities (International  Classification  of  Diseases,  Ninth  Revision,  Clinical 
Modification  classification  22) and use of medication (Anatomical  Therapeutic  Chemical 
Classification System classification 23) were retrieved from the patients’ medical records and 




Two a priori sample size calculations were undertaken. First, a mixed model sample size 
calculation 24 was based upon a 0.5 correlation between repeated measurements, 0.3 
variance of the random intercept, 0.3 residual variance, a true effect size of 0.5, a desired 
power of 80%, and a two-sided alpha of 0.05. This resulted in a total sample size of 152. 
Considering this sample size, an additional calculation for the binary PAI outcomes in a 
logistic regression model 25 was performed to detect a true odds ratio (OR) = 1.65 with 
true binary probability 0.3 and a desired power of 80%. Accounting for a potential 10% 
withdrawal rate, the required total number of participants was approximately 165. 
Calculation of MAS-P scores
The degree in which the 12 MAS-P scores can be reliably summarized as an average value was 
investigated by the two-way intra class correlation (ICC) coefficient (type: average, two-way, 
agreement). A cut-off ICC value of .80, which indicates a strong correlation 26, was desired 
for the average MAS-P score. Furthermore, to what degree the 12 MAS-P measurements 
have a dominating direction of variation was investigated by principal component analysis.
Baseline characteristics and differences in characteristics between tertiles of AGE levels
AGE levels were categorized in tertile groups and 1-way analysis of variance tests were 
performed for continuous data and χ2 tests for frequency data, with post hoc analysis (Tukey 
for 1-way analysis of variance), if relevant, to analyse differences in characteristics between 
the 3 AGE level groups.
Association between AGE levels and paratonia presence and severity
To investigate the association between AGE levels and the presence of paratonia, a 
generalized linear mixed model was used, estimated by restricted maximum likelihood, and 
taking the presence of paratonia (PAI) as a response at each of the 3 visits (baseline, 6 
months, 12 months). To investigate the association between AGE levels and the severity 
of paratonia, a linear mixed model (LMM) was used, estimated by restricted maximum 
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likelihood, and taking the severity of paratonia measured by MAS-P as a response at each of 
the 3 visits (baseline, 6 months, 12 months). In both models, the association was statistically 
controlled for the (fixed) effects of sex, age, polypharmacy, dementia duration, cognition 
(MMSE), chronic kidney disease, cardiovascular disease, cerebral vascular disease and DM 8,27 
as well for random effects of the participants. Backward model selection was used for 
detecting statistically significant explanatory variables. During this process, the fixed effects 
of AGE levels and visits were always retained to explore for longitudinal effects. 
To further investigate the within participant association of AGEs with paratonia severity 
(MAS-P), the differences in paratonia severity (MAS-P) and in AGEs, respectively, between 
Visit 3 and Visit 1 were computed separately for participants without paratonia, with incident 
paratonia, and persistent paratonia. To investigate changes in AGE levels and in paratonia 
severity (MAS-P), paired sample t-tests were performed. Change in paratonia proportion 
was analyzed by χ2 tests. The association of these within-participant differences between 
AGEs and paratonia severity (MAS-P) were further investigated by correlation and simple 
regression. Data were analyzed using R version v3.2.0 and SPSS version v 22 and taking a P 
value of < .05 as statistically significant. 
RESULTS
A flowchart of the enrolment of participants is presented in figure 1. A total of 144 participants 
were finally included at baseline.  After 1 year, 26 participants (18%) were lost to follow-up: 
11 had deceased and 15 were transferred to unknown addresses or became too ill to be 
reassessed (Figure 1). For comorbidity and medication use of 11% of the patients (n = 16), 
information was not accessible in the medical records.
Baseline Characteristics and Differences in Characteristics Between Tertiles of AGE Levels
Table 1 illustrates baseline characteristics of the participants according to the tertiles of AGE 
levels; 56.3% female and 43.7% male, with a mean (standard deviation [SD]) age of 80.7 
[7.7] years. Participants had a mean (SD) dementia duration since diagnosis of 29.8 (35.9) 
months and had a mean (SD) of 1.18 (1.1) comorbidities. Paratonia was diagnosed in 60 
participants (41.7%). 
The ICC for paratonia severity (MAS-P) scores of visit 1 to 3e was high (> .90), and principal 
component analysis indicated strong evidence that the MAS-P has 1 underlying construct 




Association Between AGE levels and Paratonia Presence and Severity
The presence (PAI) and severity (MAS-P) of paratonia were both significantly more evident 
in the highest AGE level tertile compared to the lowest tertile. Participants in the highest 
AGE level tertile demonstrated a substantially greater number of comorbidities and showed 
a significantly higher prevalence of DM (table 1). 
The mixed model analyses reveal a significant time effect as well as a significant regression 
type of association between AGEs and paratonia and AGES and paratonia severity (MAS-P). 
Table 2 shows that paratonia is significantly associated with the AGE levels (OR = 3.47, 95% 
CI: 1.87 - 6.44, P <.001) and with the progression over a time span of 1 year (OR = 2.89, 95% 
CI: 1.41 - 5.90, P = .004).
Figure 1. Study Flow Chart





Tertiles of AGE levels 
Total Low
SAF ≤ 2.5 AU
Middle
SAF 2.5 AU >< 3.1 AU
High
SAF ≥ 3.1 AU
P Value
Participants, n (%) 144             52 (36,1%) 40   (27,8%)  52   (36.1%) .78
Male, n (%) 63 (43.7%) 16 (30.8%) 19   (47.5%)  28   (53.8%) .51
Age, years 80.7   (7.7) 79.9   (8.9) 80.5     (7.3)     81.5     (6.6) .56
Dementia duration, months* 29.8 (35.9) 35.9  (46.6) 30.36 (29.4) 22.90 (24.9) .24
Co morbidities, n* 1.18 (1.1) 0.9   (1.0) 1.15   (1.0) 1.51   (1.2) .018†
  Cardio vascular disease, n (%)* 41 (32.0%) 14 (11.0%) 13   (10.0%) 14   (11.0%) .55
  Cerebral vascular Disease, n (%)* 22 (17.2%) 6   (4.7%) 5     (3.9%) 11     (8.6%) .26
  Diabetes, n (%)* 37 (28.9%) 11   (8.6%) 6     (4.7%) 20   (15.6%) .020†, .015‡
  Cancer, n (%)* 14 (11.0%) 2   (1.7%) 3     (2.3%) 9     (7.0%) .015†
  COPD, n (%)* 14 (11.0%) 4   (3.1%) 6     (4.7%) 4     (3.1%) .30
  Chronic kidney disease, n (%)* 11   (8.6%) 4   (3.1%) 2     (1.7%) 5     (3,9%) .72
  Systemic, n (%)*   8   (6.3%) 3   (2.3%) 3     (2.3%) 2     (1.7%) .70
  Digestive tract, n (%)*   6   (4.7%) 1   (0.8%) - 5     (3.9%) .048‡
Polypharmacy (≥ 5 medications), n (%)* 71 (55.5%) 25 (19.5%) 17   (13.3%) 29   (22.7%) .36
MMSE, score 0-30 19.4   (5.4) 19.14 (5.1) 19.10   (5.4) 19.94   (5.8) .69
GDS, score 1-7 3.84   (1.0) 3.85 (1.0) 3.93   (1.0) 3.77   (1.0) .76
Paratonia, n (%) 60   (41.7%) 13     (25%)           18     (45%)   29   (55.8%) .001†
MAS-P, score 0-4 0.40 (0.40) 0.27  (0.26) 0.43 (0.35)   0.52 (0.49) .003†
AGEs = advanced glycation end-products; AU = arbitrary units (ie, the output units of the AGE reader); COPD = chronic obstructive 
pulmonary disease; GDS = Global Deterioration Scale; MAS-P = modified Ashworth scale for paratonia; MMSE = Mini Mental State 
Examination; SAF = skin autofluorescence (AGE reader). 
Data represent mean values (SD) unless indicated otherwise.
*: Based on GP medical files n=128.
†: High vs low tertile.
‡: High vs middle tertile.
Table 2. Association between AGE levels and Paratonia Presence (PAI)
Paratonia presence
Estimate Odds Ratio 95% CI P value
lower limit upper limit
(Intercept) -4.16 0.02 0.00 0.10 <.001
AGE levels 1.24 3.47 1.87 6.44 <.001
Visit2 0.08 1.08 0.56 2.08 .819
Visit3 1.06 2.89 1.41 5.90 .004
GLMM, generalized linear mixed model. 
GLMM was obtained after removing statistically insignificant variables. Response variable: PAI (the presence of 
paratonia “no/yes”).  Explanatory variable: AGE levels.
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Table 3.  Association between AGE levels and Paratonia Severity (MAS-P)
Paratonia severity
Estimate 95% CI P value
lower limit upper limit
(Intercept)  0.30 0.04  0.56 .026
MMSE -0.02 -0.03 -0.01 <.001
AGE levels  0.17  0.11  0.23 <.001
Visit2 -0.01 -0.08  0.05 .576
Visit3  0.18  0.12  0.25 <.001
LMM, linear mixed model. 
LMM was obtained after removing statistically insignificant variables. Response variable: MAS-P. Explanatory 
variable: AGE levels.
Table 3 indicates that, after correction for MMSE, paratonia severity is significantly associated 
with the AGE levels (β = 0.17, 95% CI: 0.11 - 0.23, P <.001) and with the progression over 
a time span of 1 year (β = 0.18, 95% CI: 0.12 - 0.25, P <.001). To further investigate the 
degree in which the latter is due to within participant association, we computed respectively 
the difference in paratonia severity (MAS-P) and in AGEs between visit 3 and visit 1. These 
within participant difference were further investigated on degree of association and the 
regression of AGEs on paratonia severity (MAS-P).
The 1-year development of AGE levels and paratonia presence (PAI) and severity (MAS-P) is 
presented in Table 4. One hundred and eighteen participants (82%) completed this study, 
of whom 84 showed no paratonia at baseline. After a 1-year follow-up, 32 participants 
developed paratonia, resulting in a 1-year incidence of 22.2 %. Of the remaining participants, 
40 exhibited no paratonia, 35 having persistent paratonia and 11 participants varied in 
paratonia status throughout the study.
In participants with paratonia throughout the study the AGE levels and severity (MAS-P) of 
paratonia increased. Participants who developed paratonia showed the highest increase 
in AGE levels and paratonia severity (MAS-P). AGE levels remained stable in participants 
without paratonia after 1-year follow up.
The difference in AGE levels change in 1 year between participants who developed paratonia 
and participants without paratonia was significant (95% CI: -0.40 to -0.04, P = .016). There 
was no significant difference in AGE levels change between participants with persistent 
paratonia and without paratonia nor between participants with persistent paratonia and 
participants who developed paratonia (P = .052 and P = .99, respectively). Changes in AGE 
levels between visits 3 and 1 were not significantly correlated (r = .17, P = .062) with changes 
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in paratonia severity (MAS-P) over this time period. In the group that developed paratonia 
the results were similar (r = .17, P = .344). In addition, the linear regression shows that 
change in AGE levels is not predictive for changes in paratonia severity (MAS-P) (β = 0.14, 
95% CI: -0.007 to 0.296, P = .062) even after adjusting for baseline characteristics (β = 0.13, 
95% CI: -0.44 to 0.299, P = .144) as shown in Table 5.
Table 4. One-Year Development of AGE Levels and Paratonia Presence (PAI) and Severity (MAS-P)
Visit 1 Visit 2 Visit 3 Difference Visit 1-Visit 3
95% CI 
lower limit          upper limit 
All participants 
    Paratonia (%) 41.7 43.8 § 56.8*
    MAS-P   0.40 (0.40) 0.40 (0.38) † 0.58 (0.41) * -0.29 -0.14
    AGE levels   2.8   (0.7) 2.9   (0.7) * 3.0   (0.7) * -0.25 -0.08
Participants with paratonia 
throughout the year (n=35)
    MAS-P      0.64 (0.32) 0.60 (0.43) † 0.89 (0.42) * -0.38 -0.12
    AGE levels   3.1   (0.8) 3.2   (0.7) 3.4   (0.6) * -0.46 -0.06
Participants without paratonia 
throughout the year (n=40)
    MAS-P 0.16 (0.20) 0.19 (0.22) † 0.28 (0.22) * -0.19 -0.05
    AGE levels 2.7   (0.7) 2.7   (0.7) 2.7   (0.7)
Participants developing paratonia 
throughout the year (n=32)
    MAS-P 0.18 (0.20) 0.29 (0.27) § 0.65 (0.37) * -0.60 -0.35
    AGE levels 2.7   (0.6) 2.8   (0.7) 3.0   (0.5) * -0.38 -0.13
    AGE levels change (delta visit 3/ visit 1) ‡ -0.40 -0.04
AGE = advanced glycation end-product; MAS-P = modified Ashworth scale for paratonia. 
Data represent mean values (SD) unless indicated otherwise.
§:  Significantly different from visit 1 and visit 3.
*:  Significantly different from visit 1.
†:  Significantly different from visit 3.




It was ascertained that AGE levels are associated with the presence and severity of paratonia 
in patients in early stage AD and AD/VaD. During the course of 1 year, paratonia presence 
and severity as well as AGE levels increased. 
This study reveals a statistically significant increase of paratonia severity (MAS-P) of 0.17 
following a 1-year duration. The mixed model analyses revealed a significant association, 
but mixed models are an average of within participant differences over time and between 
participant differences at the different time (visit) points. Therefore, we decided to conduct 
more analyses (correlation and regression analyses on the change scores) to provide 
more clarity. The effect of time in the mixed model is a within effect. Data from the extra 
analysis provide some evidence for association between paratonia severity and AGEs 
within participants (correlation and simple regression show both borderline significance of 
.062). Therefore the significance of the effect (regression coefficient) from mixed models 
of AGEs on paratonia severity is caused by within participant association, and by between 
(cross-sectional per visit) participant association. The fact that the effect is small in size is 
most probably caused by a relative small time span of 1 year between visit 1 and visit 3. 
Changes in paratonia severity could be explained by the occurrence of new paratonia cases 
and due to slow aggravation of paratonia severity in those patients who already exhibited 
paratonia at baseline. Furthermore, because severe paratonia is related to profound 
Table 5. Association Between 1-Year Change in AGE Levels and change in Paratonia Severity (MAS-P)
MAS-P change
Estimate 95% CI P value
lower limit upper limit
(Intercept) -0.37 -1.42 0.68 .481
Sex -0.04 -0.21 0.13 .674
Age 0.01 -0.00 0.02 .145
Polypharmacy -0.02 -0.21 0.17 .865
Chronic kidney disease 0.12 -0.19 0.42 .452
Diabetes 0.05 -0.14 0.24 .602
Dementia duration 0.00 -0.00 0.00 .383
Cardio vascular disease 0.06 -0.13 0.25 .545
Cerebral vascular disease 0.03 -0.20 0.26 .776
MMSE -0.01 -0.03 0.00 .113
AGE levels change 0.13 -0.04 0.30 .144
Linear regression model. Corrected for possible explanatory variables.
Response variable: MAS-P change (delta visit 3/ visit1).  Explanatory variable: AGE levels change (delta visit 3/ visit 
1).
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limitations in functional mobility, as mentioned in the introduction, this relationship is of 
clinical importance.  It has to be considered that our cohort existed of early stage dementia 
patients in which paratonia was less severe resulting in a limitation of range in MAS-P 
scores. The MAS has a tendency to cluster scores in the lower range, limiting the ability 
to discriminate between patients with low scores 28. The follow-up period of 1 year was 
probably too brief to detect a significant correlation between changes in AGE levels and 
changes in paratonia severity, however, it does provide an estimation on the progression 
speed on AGEs accumulation as well as the worsening of paratonia within patients with 
early stage dementia. In a range between 0 and 4 on the MAS-P, an increase of 0.17 in 1 
year seems to be clinically moderate in size. However, with a typical clinical disease duration 
of 8 to 10 years 29, it  becomes clinically relevant  when these differences are extrapolated. 
Further research with a longer follow up is necessary to investigate how changes in AGE 
levels are related to changes in paratonia severity during the course of AD, AD/VaD or other 
dementias. 
The speed by which collagen tissue is stretched, influences the degree to which the tissue 
elongates. The more rapid a movement occurs, the stiffer the connective tissue behaves 30. 
One of the criteria for diagnosing paratonia is the perceived increase in resistance during 
passive movement acceleration by the assessor and is exactly what can be expected from 
cross-linking AGE accumulation in peripheral tissue. This could imply that in early stage 
dementia, 2 phenomena are responsible for the development of paratonia: a central cerebral 
factor because of the AD pathology and a peripheral factor because of AGE accumulation. It 
could be hypothesised that, in early stage AD, AGE accumulation is a greater factor initiating 
movement stiffness and that the central cerebral factor builds up or even accelerates 
paratonia. Future research is necessary to study this more in depth. 
It is of importance to investigate whether paratonia could be postponed or movement 
stiffness could be improved by reducing AGE levels. Excessive elevation of glucose 
concentration, such as in DM, most likely accelerates the  glycation of proteins 7,8,27. Intensive 
glycaemic control may be a method for decreasing AGEs formation. For this study, we did 
not request permission to obtain blood samples from our participants as we expected that 
this would hamper ethical approval. Therefore, as a consequence, glycaemia could not be 
controlled in this study. 
AGEs are not only produced endogenously; they can also be ingested via food. Specific 
circulating AGE levels correlate to dietary consumption, especially  in food that has been 
processed at very high temperatures, such as frying, broiling, grilling and roasting 9. Therefore, 
dietary intake is a possible factor that can be influenced 31. However, evidence of the harmful 
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effects of long-term exposure to dietary AGEs are currently inconclusive 32. Regular physical 
exercise could also attenuate the formation and accumulation of AGEs 7,33,34, however, 
literature regarding the effects of physical exercise on AGEs formation is minimal, and the 
optimal exercise modalities remain ambiguous 33. Pharmacological approaches to prevent 
AGE formation or AGE accumulation can be divided into several classes as a function of their 
mechanism of action: AGE absorption inhibitors, AGE formation inhibitors, AGE cross–link 
breakers, RAGE antagonists, and AGE binders. Several of these pharmacological strategies 
with anti-AGEs effects are currently being studied, but results show conflicting evidence 35 
and additional research is necessary to obtain an optimal combination of possible strategies. 
Studies investigating the AGE targeted interventions on paratonia could be considered as a 
proof of concept underpinning the causal relationship of AGEs and paratonia.
Strength and Limitations
This is the first study investigating the association between AGEs and paratonia. The primary 
strength of this study is its longitudinal design with 3 assessments. A prolonged study over 
several years in a larger cohort could result in improved insight into the long- term effects 
and the within participant relation of AGEs on the development of paratonia. In fact the 
AGE formation, from a reversible to an irreversible end product takes weeks to months 7,36. 
The (collagen) tissue accumulation and its potential impact on paratonia, is a process 
that generally costs several months to years. Further studies involving dementia patients 
in very early stages over a longer time period (e.g., several years) could help to enlighten 
this aspect. In addition, a causal relationship cannot be inferred and further longitudinal 
studies over several years are needed to investigate this.  Another strength of this study 
is that patients were included spread across The Netherlands (urban and rural), which 
created a study sample representative for this population. This study also has a number of 
limitations. First, the calculated number of 152 participants was not reached. However, the 
study did comprise a reasonable number of 144 participants for baseline and 118 for follow 
up analysis. Second, it was not feasible to indicate which type of AGEs (e.g., cross-linking 
or non-cross-linking) was responsible for the findings because of the limitations of the AGE 
reader. Future fundamental research is necessary to further explore this in order to enable 
targeted interventions to postpone the development or worsening of paratonia in patients 
with dementia.




This study suggests that elevated AGE levels are a contributing factor to the presence of 
paratonia as well as its severity in patients with early stage AD or AD/VaD. These results 
provide a new perspective on paratonia. Future research is necessary to investigate the 
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